Anxiolytic Effects of Single-Dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia.

Trial Profile

Anxiolytic Effects of Single-Dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Phobic disorders
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms QUISS
  • Most Recent Events

    • 30 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top